PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.




PMID- 28739772
OWN - NLM
STAT- MEDLINE
DA  - 20170725
DCOM- 20170803
LR  - 20170803
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 37
IP  - 8
DP  - 2017 Aug
TI  - Efficacy and Safety of Nab-Paclitaxel as Second-line Chemotherapy for Locally
      Advanced and Metastatic Non-small Cell Lung Cancer.
PG  - 4687-4691
AB  - AIM: To investigate the efficacy and safety of nanoparticle albumin-bound
      paclitaxel (nab-paclitaxel) for locally advanced or metastatic non-small cell
      lung cancer (NSCLC) as second-line chemotherapy. PATIENTS AND METHODS: We
      retrospectively reviewed the treatment of 34 patients with advanced NSCLC whose
      first-line treatment had failed. These patients received nab-paclitaxel 260 mg/m2
      on day 1 and day 8 of a 21-day cycle from July 2014 to February 2016. One cycle
      of treatment lasted 3 weeks and all patients completed more than two cycles. All 
      patients were assessed for adverse events related to treatment. RESULTS: No
      patient achieved complete response (CR); 12 patients reached partial response
      (PR), 12 patients achieved stable disease (SD) and 10 patients progressive
      disease (PD). The overall response rate (ORR) was 35.3% and the disease control
      rate (DCR) 70.6 %. There was no significant difference in either ORR or DCR
      within the subgroups. The median progression-free survival (PFS) was 5.7 months
      (95% confidence interval (CI)=3.8-7.6) and the median overall survival (OS) was 9
      months (95% CI=8.3-9.7). There was no statistical difference in OS (p=0.066), but
      subgroup analysis showed that patients with squamous carcinoma benefited more in 
      PFS (the median PFS of squamous carcinoma vs. adenocarcinoma was 7.3 months vs. 5
      months, p=0.001). Major adverse events included myelosuppression,
      gastrointestinal response, baldness, myalgia and neurotoxicity. Hypersensitivity 
      reactions were not reported. CONCLUSION: Nab-paclitaxel is an effective
      chemotherapy for locally advanced and metastatic NSCLC as treatment and has a
      superior application prospect for squamous NSCLC. Toxicity is generally mild and 
      manageable.
CI  - Copyright(c) 2017, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Wong, Wenjing
AU  - Wong W
AD  - Department of Oncology, Jinan Central Hospital, Affiliated to Shandong
      University, Jinan, P.R. China.
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China.
FAU - Sun, Ping
AU  - Sun P
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China.
FAU - Mu, Zhengbin
AU  - Mu Z
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China.
FAU - Liu, Jiannan
AU  - Liu J
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China.
FAU - Yu, Caiyan
AU  - Yu C
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China.
FAU - Liu, Aina
AU  - Liu A
AD  - Department of Oncology, Yuhuangding Hospital of Yantai, Yantai, P.R. China
      [email protected]
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (130-nm albumin-bound paclitaxel)
RN  - 0 (Albumins)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Albumins/administration & dosage/adverse effects/*therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/*drug therapy/mortality/*pathology
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/*drug therapy/mortality/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Paclitaxel/administration & dosage/adverse effects/*therapeutic use
MH  - Retreatment
MH  - Risk Factors
MH  - Survival Analysis
MH  - Treatment Outcome
OTO - NOTNLM
OT  - NSCLC
OT  - chemotherapy
OT  - nab-paclitaxel
OT  - second-line
EDAT- 2017/07/26 06:00
MHDA- 2017/08/05 06:00
CRDT- 2017/07/26 06:00
PHST- 2017/05/19 [received]
PHST- 2017/06/08 [revised]
PHST- 2017/06/09 [accepted]
AID - 37/8/4687 [pii]
PST - ppublish
SO  - Anticancer Res. 2017 Aug;37(8):4687-4691.